2019 FDA TIDES (Peptides and Oligonucleotides) Harvest

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2020 Mar 11

PMID 32151051

Citations 35

Authors

Danah Al Shaer

Othman Al Musaimi

Fernando Albericio

Beatriz G de la Torre

Affiliations

Soon will be listed here.

Abstract

2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.

Citing Articles

FDA-approved drugs featuring macrocycles or medium-sized rings.

Du Y, Semghouli A, Wang Q, Mei H, Kiss L, Baecker D Arch Pharm (Weinheim). 2025; 358(1):e2400890.

PMID: 39865335 PMC: 11771699. DOI: 10.1002/ardp.202400890.

An Improved P(V) Thio-Oligonucleotide Synthesis Platform.

Nassir M, Gherardi L, Redman R, Jin Y, Yao F, Yang Y Org Lett. 2024; 27(1):97-102.

PMID: 39700460 PMC: 11723805. DOI: 10.1021/acs.orglett.4c03980.

Porous silicon and silica carriers for delivery of peptide therapeutics.

Yan J, Siwakoti P, Shaw S, Bose S, Kokil G, Kumeria T Drug Deliv Transl Res. 2024; 14(12):3549-3567.

PMID: 38819767 PMC: 11499345. DOI: 10.1007/s13346-024-01609-7.

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms.

Al Musaimi O Biomolecules. 2024; 14(3).

PMID: 38540684 PMC: 10968328. DOI: 10.3390/biom14030264.

Peptide-encoding gene transfer to modulate intracellular protein-protein interactions.

Taya T, Kami D, Teruyama F, Matoba S, Gojo S Mol Ther Methods Clin Dev. 2024; 32(2):101226.

PMID: 38516692 PMC: 10952081. DOI: 10.1016/j.omtm.2024.101226.

References

Bargh J, Isidro-Llobet A, Parker J, Spring D . Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019; 48(16):4361-4374. DOI: 10.1039/c8cs00676h. View

Al Shaer D, Al Musaimi O, Albericio F, de la Torre B . 2018 FDA Tides Harvest. Pharmaceuticals (Basel). 2019; 12(2). PMC: 6631726. DOI: 10.3390/ph12020052. View

Miller M, Smith J, Norman J, Clayton A . Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018; 23(3):223-230. DOI: 10.1080/14728214.2018.1527901. View

Graham M, Gu X, Ginader T, Breheny P, Sunderland J . Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis. J Nucl Med. 2017; 58(9):1452-1458. PMC: 6944175. DOI: 10.2967/jnumed.117.191197. View

Diamantis N, Banerji U . Antibody-drug conjugates--an emerging class of cancer treatment. Br J Cancer. 2016; 114(4):362-7. PMC: 4815767. DOI: 10.1038/bjc.2015.435. View

Janas M, Harbison C, Perry V, Carito B, Sutherland J, Vaishnaw A . The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies. Toxicol Pathol. 2018; 46(7):735-745. PMC: 6249674. DOI: 10.1177/0192623318792537. View

Zhang X, Goel V, Robbie G . Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis. J Clin Pharmacol. 2019; 60(5):573-585. PMC: 7187331. DOI: 10.1002/jcph.1553. View

McGregor B, Sonpavde G . Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. Expert Opin Investig Drugs. 2019; 28(10):821-826. DOI: 10.1080/13543784.2019.1667332. View

Dal Corso A, Cazzamalli S, Gebleux R, Mattarella M, Neri D . Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates. Bioconjug Chem. 2017; 28(7):1826-1833. PMC: 5521252. DOI: 10.1021/acs.bioconjchem.7b00304. View

10.

Allerson C, Sioufi N, Jarres R, Prakash T, Naik N, Berdeja A . Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005; 48(4):901-4. DOI: 10.1021/jm049167j. View

11.

Menda Y, Ponto L, Schultz M, Zamba G, Watkins G, Bushnell D . Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 2013; 42(6):937-43. PMC: 3898770. DOI: 10.1097/MPA.0b013e318287ce21. View

12.

Khor L, Loi H, Sinha A, Tong K, Goh B, Loh K . (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma. Head Neck. 2015; 38(4):E76-80. DOI: 10.1002/hed.24164. View

13.

Both S . Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder. Curr Sex Health Rep. 2017; 9(4):192-199. PMC: 5711968. DOI: 10.1007/s11930-017-0124-3. View

14.

Han T, Zhao B . Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014; 42(11):1914-20. DOI: 10.1124/dmd.114.058586. View

15.

Fabrikant J, Touloei K, Brown S . A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol. 2013; 12(7):775-9. View

16.

Sawyer T, Sanfilippo P, Hruby V, Engel M, Heward C, Burnett J . 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980; 77(10):5754-8. PMC: 350149. DOI: 10.1073/pnas.77.10.5754. View

17.

Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T . The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019; 67(3):173-185. DOI: 10.1248/cpb.c18-00744. View

18.

Dorywalska M, Dushin R, Moine L, Farias S, Zhou D, Navaratnam T . Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design. Mol Cancer Ther. 2016; 15(5):958-70. DOI: 10.1158/1535-7163.MCT-15-1004. View

19.

Ogitani Y, Abe Y, Iguchi T, Yamaguchi J, Terauchi T, Kitamura M . Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. Bioorg Med Chem Lett. 2016; 26(20):5069-5072. DOI: 10.1016/j.bmcl.2016.08.082. View

20.

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N . DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016; 22(20):5097-5108. DOI: 10.1158/1078-0432.CCR-15-2822. View